WGS Share Price Performance
US$90.67
12.67 (16.24%)
46.7% undervalued intrinsic discount
US$170.00
Fair Value
Price US$90.67
AnalystConsensusTarget US$170.00
AnalystLowTarget US$153.00
AnalystHighTarget US$156.97
Fair ValueUS$170.00
Share Pricen/a
GeneDx Holdings Corp. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 52 Fair Values set on narratives written by author
WGS Community Narratives
AN
Fair Value US$170 46.7% undervalued intrinsic discount
WGS: Customer Conversion And Market Expansion Will Shape Rare Disease Diagnostics
0users have liked this narrative
0users have commented on this narrative
25users have followed this narrative
AN
Fair Value US$153 40.7% undervalued intrinsic discount
Government Cost-Containment And Tightening Privacy Laws Will Squeeze Margins
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value US$156.97 42.2% undervalued intrinsic discount
Genomics And AI Integration Will Expand Precision Healthcare Adoption
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
WGS: Customer Conversion And Market Expansion Will Shape Rare Disease Diagnostics
Key Takeaways Accelerating adoption of genomics in pediatrics and enhanced AI platforms drive growth, efficiency, and margin improvement while reinforcing competitive advantage. Increasing reimbursement, enriched rare disease datasets, and global biopharma partnerships support recurring revenues, premium pricing, and high barriers to entry.Read more
228
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
25users have followed this narrative
AN
US$170
46.7% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
24.78% p.a.
Profit Margin
9.06%
Future PE
91.12x
Price in 2029
US$214.72
Government Cost-Containment And Tightening Privacy Laws Will Squeeze Margins
Key Takeaways Rising regulatory and reimbursement pressures threaten to squeeze margins and limit GeneDx's ability to capitalize on its genomic database. Intensifying industry competition and slow clinical adoption risk eroding market share and dampening growth prospects.Read more
20
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$153
40.7% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
22.15% p.a.
Profit Margin
8.31%
Future PE
95.29x
Price in 2029
US$193.13
Genomics And AI Integration Will Expand Precision Healthcare Adoption
Key Takeaways Exclusive data, AI platform, and strategic integration efforts position GeneDx for sustained market leadership, margin expansion, and outperformance relative to analyst expectations. Shifts in testing guidelines and biopharma partnerships will catalyze broad adoption, recurring high-margin revenues, and accelerating competitive advantage through network effects.Read more
22
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$156.97
42.2% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
23.89% p.a.
Profit Margin
18.84%
Future PE
47.11x
Price in 2028
US$186.17
Trending Discussion
Recently Updated Narratives
AN
WGS: Prenatal Whole Genome Sequencing Launch Will Expand High-Value Anomaly Testing Market
Fair Value: US$170 46.7% undervalued intrinsic discount
25 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
WGS: Prenatal Sequencing Launch Will Reshape Future Prospects For This Undervalued Leader
Fair Value: US$153 40.7% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Genomics And AI Integration Will Expand Precision Healthcare Adoption
Fair Value: US$156.97 42.2% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
GeneDx Holdings Corp. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 23, 2026
- 0.072
- 69.65%
- 0.52%
- 17.6%
About WGS
- Founded
- n/a
- Employees
- 1000
- CEO
- WebsiteView website
GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company also develops an AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. The company is headquartered in Stamford, Connecticut.
